Latest Competition News

International Graphite Limited has signed a non-binding letter of intent with Alkeemia S.p.A to access graphite purification tolling services at a new Italian plant starting early 2026, aiming to boost its high-purity graphite supply while minimizing capital costs.

CONNEQT Health’s Pulse arterial health monitor sales have outpaced expectations with over 200% growth in the December quarter, driven by efficient marketing and early subscription uptake.

Recce Pharmaceuticals has won a significant Australian Government R&D tax incentive, unlocking up to A$85 million for its synthetic anti-infective programs worldwide, including a pivotal Phase 3 clinical trial.

HITIQ Limited has successfully completed the initial tranche of a $900,000 placement, issuing over 40 million shares with attached options, while director participation awaits shareholder approval.

ECS Botanics is strategically preparing for entry into the US medicinal cannabis market, leveraging its EU-GMP certification and proprietary genetics amid evolving regulatory landscapes.

Augustus Minerals announces the sudden resignation of CEO Dr James Warren, with interim leadership stepping in as the company begins its search for a successor.

Bank of Queensland Limited has announced a fully franked quarterly distribution of AUD 1.2412 per Capital Note 3 security, payable in March 2026. The distribution reflects a 4.9784% annualised rate based on the BBSW plus a margin.

AWAG has accelerated its growth trajectory by doubling its authorised representatives and increasing funds under management to $3.6 billion through strategic investments in Avalon Financial Services and SWR Chartered Accountants.

Centrepoint Alliance forecasts a robust 13% increase in EBITDA for the first half of FY26, driven by strong adviser recruitment and platform scaling, cementing its position as the second-largest licensee in Australia.

DroneShield has landed a $49.6 million contract to supply handheld counterdrone systems to a European military customer, with deliveries and payments expected to complete by Q1 2026.

Immutep Limited reports robust progress in its pivotal Phase III TACTI-004 trial for advanced non-small cell lung cancer, with over 120 clinical sites activated across 27 countries including the US. Patient enrolment has reached 38% of the target, keeping key milestones on track.

Perseus Mining has terminated its binding offer for Predictive Discovery following the acceptance of a revised merger agreement between Predictive and Robex Resources. Despite the improved terms for Predictive shareholders, Perseus remains unconvinced and holds the door open for future moves.